| # | Country | Total Patents | |
|---|---|---|---|
| #1 | EPO (European Patent Office) | 6 | |
| #2 | Canada | 5 | |
| #3 | WIPO (World Intellectual Property Organization) | 5 | |
| #4 | Brazil | 3 | |
| #5 | Mexico | 3 | |
| #6 | Sweden | 3 | |
| #7 | United States | 3 | |
| #8 | Australia | 2 | |
| #9 | China | 2 | |
| #10 | Israel | 2 | |
| #11 | Norway | 2 | |
| #12 | Poland | 2 | |
| #13 | Hungary | 1 | |
| #14 | Republic of Korea | 1 | |
| #15 | Russian Federation | 1 |
| # | Industry | |
|---|---|---|
| #1 | Pharmaceuticals | |
| #2 | Medical technology | |
| #3 | Micro-structure and nano-technology | |
| #4 | Chemical engineering | |
| #5 | Measurement | |
| #6 | Biotechnology | |
| #7 | Environmental technology | |
| #8 | Organic fine chemistry |
| # | Technology | |
|---|---|---|
| #1 | Medical preparations | |
| #2 | Syringes | |
| #3 | Therapeutic chemical compounds | |
| #4 | Separation | |
| #5 | Nanostructure applications | |
| #6 | Analysing materials | |
| #7 | Object sterilising | |
| #8 | Climate change adaptation technologies | |
| #9 | Peptides | |
| #10 | Heterocyclic compounds |
| # | Name | Total Patents |
|---|---|---|
| #1 | Nilsson Rune | 31 |
| #2 | Sandberg Bengt E B | 19 |
| #3 | Sandberg Bengt | 13 |
| #4 | Wilbur Scott | 5 |
| #5 | Rudbaeck Charlotte | 4 |
| #6 | Maddock Stephen W | 2 |
| #7 | Wilbur Scott D | 1 |
| #8 | Rune Sandberg Bengt Nilsson | 1 |
| #9 | Norrgren Kristina | 1 |
| #10 | Lindgren Lars | 1 |
| Publication | Filing date | Title |
|---|---|---|
| CN1738645A | Antilymphoma targeting agents with effector and affinity functions linked by a trifunctional reagent | |
| CA2509103A1 | Antilymphoma targeting agents with effector and affinity functions linked by a trifunctional reagent | |
| WO0230474A1 | Kit for intraperitoneal administration and extracorpeal removal of a drug | |
| HU0401953A2 | Biotin derivatives | |
| CA2336739A1 | Trifunctional reagent for conjugation to a biomolecule | |
| IL137302A | Apparatus for use in connection with removal of elements, especially exogenous antibodies, from blood or plasma | |
| US6251394B1 | Method and a system for enhanced in vivo clearance of diagnostic and/or therapeutic agents by extracorporeal depletion, and the use of said agents for said purpose |